Edwards Lifesciences (EW) Current Assets (2009 - 2026)

Edwards Lifesciences' Current Assets history runs 18 years deep, the most recent figure standing at $6.2 billion for Q1 2026.

• On a quarterly basis, Current Assets changed 0.26% year-over-year to $6.2 billion in Q1 2026; TTM through Mar 2026 was $6.2 billion, a 0.26% change from a year earlier, with the FY2025 full-year figure at $6.7 billion, up 7.22% from the prior year.
• Current Assets declined to $6.2 billion in Q1 2026 per EW's latest filing, from $6.7 billion in the prior quarter.
• Across five years, Current Assets topped out at $6.7 billion in Q4 2025 and bottomed at $3.1 billion in Q4 2022.
• The 5-year median for Current Assets is $4.2 billion (2024), against an average of $4.8 billion.
• Across the five-year window, Current Assets surged 65.4% in 2024 and slipped 5.48% in 2025, its largest moves.
• Year by year, Current Assets stood at $3.1 billion in 2022, then jumped by 30.36% to $4.0 billion in 2023, then jumped by 55.74% to $6.3 billion in 2024, then climbed by 7.22% to $6.7 billion in 2025, then dropped by 7.57% to $6.2 billion in 2026.
• Per Business Quant, the three latest EW Current Assets figures stand at $6.2 billion (Q1 2026), $6.7 billion (Q4 2025), and $6.4 billion (Q3 2025).